ESMO: Merck Sees Keytruda-Lenvima Potential In Melanoma, Hard-To-Treat Cancers
Also Promising In Ovarian And Colorectal
Keytruda-Lenvima picked out as pick of combination therapies from the European cancer congress.
You may also be interested in...
Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Sanofi is playing catch-up in oncology and hopes Synthorx’s expertise will help the group advance.